#Obesity medicine
Chronic weight management as a clinical specialty.
Tirzepatide lean-mass review
A 2026 review found that tirzepatide weight loss mostly came from fat, but lean mass also fell and muscle function was not measured.
New amylin agonists for obesity and T2D
Zenagamtide, eloralintide and CagriSema have early to late-stage results in obesity and type 2 diabetes. Their evidence is not interchangeable.
Semaglutide and taste in mice
A 2026 mouse study found preserved taste responses during chronic semaglutide treatment, despite changes in sucrose-directed behavior.
A two-timepoint semaglutide brain map
A mouse study mapped semaglutide-linked activity across more than 500 brain areas using two timepoints, finding 24 engaged regions.
Surgery vs semaglutide and tirzepatide
A 44,025-person record study associated bariatric surgery with more weight loss than semaglutide or tirzepatide, but it was not randomized.
Tirzepatide response after eight weeks
A SURMOUNT post hoc analysis linked early tirzepatide weight response with larger 72-week changes, while later responders still lost weight.
Adolescent GLP-1 use: what remains unknown
A 2026 commentary reviews skeletal, reproductive and psychosocial questions around semaglutide and other GLP-1 drugs in adolescents.
Hypothalamic Obesity in Craniopharyngioma
A 2026 review found different obesity patterns after pediatric and adult craniopharyngioma, while direct age comparisons remain absent.
Oral semaglutide cognition cohort
A retrospective cohort linked oral semaglutide with fewer new cognitive-impairment cases than DPP-4 inhibitors, but it cannot prove prevention.
Semaglutide and a thyroid cancer case
A papillary thyroid cancer case during semaglutide use cannot establish causation, and larger human studies have not confirmed excess risk.
Semaglutide, Low Testosterone, Nine Men
An exploratory study of nine men ties semaglutide to shifted DNA methylation in obesity-related low testosterone, and it is far too small to prove anything.
An RNA Therapy for Muscle Loss on GLP-1s
In mice, a new RNA-based therapy paired with semaglutide preserved more lean mass than semaglutide alone, though it remains far from human use.